Krystal Biotech Inc Insider Trading
Every director, officer and 10% holder of Krystal Biotech Inc has to report each trade in its stock within two business days of making it. This is those filings.
KRYS on carbonthat →Purchases and sales
Open-market trades only — the lines where someone chose to buy or sell at the going price.
| Insider | Action | Value |
|---|---|---|
| Suma KrishnanPresident, R&D2026-09-04520 shat $354.54 | Sale10b5-1 plan | $184.4K |
| Suma KrishnanPresident, R&D2026-09-042K shat $355.57 | Sale10b5-1 plan | $713.3K |
| Suma KrishnanPresident, R&D2026-09-043.3K shat $356.37 | Sale10b5-1 plan | $1.2M |
| Suma KrishnanPresident, R&D2026-09-044K shat $357.57 | Sale10b5-1 plan | $1.4M |
| Suma KrishnanPresident, R&D2026-09-043.2K shat $358.42 | Sale10b5-1 plan | $1.1M |
| Suma KrishnanPresident, R&D2026-09-043.4K shat $359.39 | Sale10b5-1 plan | $1.2M |
| Suma KrishnanPresident, R&D2026-09-042.3K shat $360.47 | Sale10b5-1 plan | $836.3K |
| Suma KrishnanPresident, R&D2026-09-041.2K shat $361.61 | Sale10b5-1 plan | $449.1K |
| Suma KrishnanPresident, R&D2026-09-042K shat $362.65 | Sale10b5-1 plan | $722.4K |
| Suma KrishnanPresident, R&D2026-09-04565 shat $363.34 | Sale10b5-1 plan | $205.3K |
| Suma KrishnanPresident, R&D2026-09-041.3K shat $364.48 | Sale10b5-1 plan | $484.4K |
| Suma KrishnanPresident, R&D2026-09-04826 shat $365.41 | Sale10b5-1 plan | $301.8K |
| Suma KrishnanPresident, R&D2026-09-04399 shat $366.56 | Sale10b5-1 plan | $146.3K |
| Krish S KrishnanPresident and CEO2026-09-04520 shat $354.54 | Sale10b5-1 plan | $184.4K |
| Krish S KrishnanPresident and CEO2026-09-042K shat $355.57 | Sale10b5-1 plan | $721.5K |
| Krish S KrishnanPresident and CEO2026-09-043.3K shat $356.37 | Sale10b5-1 plan | $1.2M |
| Krish S KrishnanPresident and CEO2026-09-044K shat $357.57 | Sale10b5-1 plan | $1.4M |
| Krish S KrishnanPresident and CEO2026-09-043.1K shat $358.42 | Sale10b5-1 plan | $1.1M |
| Krish S KrishnanPresident and CEO2026-09-043.4K shat $359.39 | Sale10b5-1 plan | $1.2M |
| Krish S KrishnanPresident and CEO2026-09-042.3K shat $360.46 | Sale10b5-1 plan | $816.8K |
| Krish S KrishnanPresident and CEO2026-09-041.2K shat $361.61 | Sale10b5-1 plan | $439K |
| Krish S KrishnanPresident and CEO2026-09-042K shat $362.65 | Sale10b5-1 plan | $728.9K |
| Krish S KrishnanPresident and CEO2026-09-04573 shat $363.34 | Sale10b5-1 plan | $208.2K |
| Krish S KrishnanPresident and CEO2026-09-041.4K shat $364.48 | Sale10b5-1 plan | $495K |
| Krish S KrishnanPresident and CEO2026-09-04847 shat $365.42 | Sale10b5-1 plan | $309.5K |
| Krish S KrishnanPresident and CEO2026-09-04405 shat $366.56 | Sale10b5-1 plan | $148.5K |
| Dino A RossiDirector2026-08-14341 shat $325.60 | Sale | $111K |
| Dino A RossiDirector2026-08-142.3K shat $326.60 | Sale | $746.9K |
| Dino A RossiDirector2026-08-145.2K shat $327.39 | Sale | $1.7M |
| Dino A RossiDirector2026-08-141.7K shat $328.52 | Sale | $554.2K |
| Dino A RossiDirector2026-08-147.4K shat $329.60 | Sale | $2.4M |
| Dino A RossiDirector2026-08-144.9K shat $330.36 | Sale | $1.6M |
| Dino A RossiDirector2026-08-143.1K shat $331.43 | Sale | $1M |
| Dino A RossiDirector2026-08-1440 shat $333.23 | Sale | $13.3K |
Source: SEC Form 4 filings, via EDGAR. A derivative line reports the shares underlying an option rather than stock outstanding, so it is marked and is not comparable with the rest. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.
More on KRYS
Follow Krystal Biotech Inc (KRYS) by email
New trades in Krystal Biotech Inc (KRYS) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.